BLX three-lens brief
Evidence-based stock research on BLX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- P/E of 8.4 — trading at a value multiple.
- Analyst mean target $69.65 — 37% above current (4 analysts).
BLX closed at $50.79 (+0.24%) as of 2026-11-12. Market cap: $1.89B. P/E (trailing) 8.4. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 8.4 — trading at a value multiple.; analyst mean target $69.65 — 37% above current (4 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $98.90M, net income $66.45M.
Why three lenses on BLX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BLX across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BLX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BLX brief"></iframe>